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Abstract
Background: Trigeminal neuralgia is one of the most characteristic and difficult to treat neuropathic pain conditions in
patients with multiple sclerosis. The present narrative review addresses the current evidence on diagnostic tests and
treatment of trigeminal neuralgia secondary to multiple sclerosis.
Methods: We searched for relevant papers within PubMed, EMBASE and the Cochrane Database of Systematic Reviews,
taking into account publications up to December 2018.
Results: Trigeminal neuralgia secondary to multiple sclerosis manifests with facial paroxysmal pain triggered by typical
manoeuvres; neurophysiological investigations and MRI support the diagnosis, providing the definite evidence of
trigeminal pathway damage. A dedicated MRI is required to identify pontine demyelinating plaques. In many patients
with multiple sclerosis, neuroimaging and surgical evidence suggests that neurovascular compression might act in
concert with the pontine plaque through a double-crush mechanism. Although no placebo-controlled trials have been
conducted in these patients, according to expert opinion the first-line therapy for trigeminal neuralgia secondary to
multiple sclerosis relies on sodium-channel blockers, i.e. carbamazepine and oxcarbazepine. The sedative and motor side
effects of these drugs frequently warrant an early consideration for neurosurgery. Surgical procedures include Gasserian
ganglion percutaneous techniques, gamma knife radiosurgery and microvascular decompression in the posterior fossa.
Conclusions: The relatively poor tolerability of the centrally-acting drugs carbamazepine and oxcarbazepine highlights
the need to develop new selective and better-tolerated sodium-channel blockers. Prospective studies based on more
advanced neuroimaging techniques should focus on how trigeminal anatomical abnormalities may be able to predict
the efficacy of microvascular decompression.
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Background
Multiple sclerosis (MS) is a chronic inflammatory disease
causing demyelination and axonal degeneration in the cen-
tral nervous system. Neuropathic pain is a common symp-
tom in patients with MS. Among the different types of
neuropathic pain, trigeminal neuralgia (TN) is a character-
istic and difficult to treat neuropathic pain condition, with a
relevant impact on the quality of life [1]. Patients with MS
experiencing TN find that daily life activities, work, mood,
recreation and overall quality of life can be disrupted [1].
In this narrative review, we aim at addressing the
current evidence on TN secondary to MS.
Methods
We searched relevant papers within the PubMed, EMBASE
and the Cochrane Database of Systematic Reviews, taking
into account publications up to December 2018. All
searches used the following keywords: multiple sclerosis
AND trigeminal neuralgia, multiple sclerosis AND facial
pain. The primary search was supplemented by a secondary
search using the bibliographies of the articles retrieved.
Only full-length, original communications were accepted,
and the search was limited to English language publica-
tions. This search yielded a total of approximately 400
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articles, which were reviewed by title and abstract for po-
tential relevance to this topic; when the title and abstract
did not clearly indicate the degree of relevance to the topic,
the article itself was reviewed.
Results
Definitions and epidemiology
The International Classification of Headache Disorders [2]
and the TN classification issued by the Special Interest
Group on Neuropathic Pain of the International Associ-
ation for the Study of Pain distinguish between classical
TN, caused by a vascular compression producing morpho-
logical changes in the trigeminal nerve root, secondary
TN, which is due to an identifiable underlying neurological
disease, and idiopathic TN [3]. In patients with idiopathic
TN even advanced diagnostic investigations fail to show a
cause. TN is characterized by recurrent, unilateral, brief,
electric shock-like pain, abrupt in onset and termination.
Pain is limited to the distribution of one or more divisions
of the trigeminal nerve and triggered by innocuous stimuli.
Additionally, there may be concomitant continuous pain of
moderate intensity within the distribution(s) of the affected
nerve division(s). Secondary TN occurs in up to 15% [4–6]
of TN patients and the diagnosis is made in the presence
of a structural abnormality affecting the trigeminal nerve
other than vascular compression, including multiple scler-
osis (MS) plaques, tumours and abnormalities of the skull
base. MS plaques are the most commonly identified abnor-
malities. Patients with MS have a 20-fold increased risk of
developing TN [7]; 1.9–4.9% of patients with MS suffer
from this neuropathic pain condition [8–12], without
differences between relapsing-remitting, secondary and
primary progressive forms [8]; conversely MS is detected
in 2%–14% of patients with TN [10].
Clinical characteristics
TN secondary to MS is, like the classical and idiopathic
TN, characterized by a sudden, usually unilateral, brief,
stabbing or electrical shock-like, recurrent pain with a
distribution that is consistent with one or more divisions of
the fifth cranial nerve. The paroxysmal attacks, last from a
fraction of a second to 2min and are typically evoked by
stimulating cutaneous or mucous trigeminal territories, i.e.
the so-called trigger zones. Gently touching the face,
washing, shaving, talking, tooth brushing, chewing,
swallowing or even a slight breeze may trigger the parox-
ysms. Stimulus-dependence is considered one of the most
striking characteristics of TN and a criterion of clinically-
established TN [3]. Patients may also report spontaneous
attacks. However, it is still an issue of controversy whether
these pain attacks are elicited by very subtle sensory stimuli
or movements or are genuine spontaneous attacks [6]. The
frequency of the pain attacks may range from 1 to over 50
a day [4, 13]. Patients with classical and idiopathic TN have
pain-free intervals of often complete remission lasting from
weeks to years, most often a few months [6]. Conversely,
there is a lack of general consensus about the occurrence of
remission periods in TN secondary to MS. Remission
periods are probably due to a reduction in excitability and
partial remyelination, but evidence is missing to support
this hypothesis [14]. These pain characteristics are easily
differentiated from other MS-related neuropathic facial
pain conditions, including ongoing pain, dysesthesias and
provoked pain. Some patients with TN secondary to MS, as
well as patients with classical and idiopathic TN, suffer
from concomitant continuous, dull, burning, or tingling
pain between the paroxysms. The distribution of continu-
ous pain coincides with that of the paroxysmal pain, and
fluctuations in intensity as well as periods of remission and
recurrence parallel those of the paroxysmal pain [6].
TN secondary to MS is, like classical and idiopathic TN,
more common in women than in men, and affects the
right side more frequently than the left side [15, 16]. TN
secondary to MS tends, however, to occur at an earlier age
in patients with MS, with age at onset ranging from 40 to
50 years [15, 16]. The first branch alone may be involved
in TN secondary to MS, though the second and/or the
third branch are involved in approximately 90% of cases
[5, 6, 15]. Although the characteristics of TN secondary to
MS are similar to those observed in classical TN, the pain
is more frequently bilateral in MS patients, with an esti-
mated 18% of patients reported to have bilateral TN [15–
17]. Clinical deficits of discriminatory sensory functions,
which are highly indicative of secondary TN, occur in 37%
of patients with secondary TN [5, 8]. Although a younger
age and trigeminal sensory deficits are associated with an
increased risk of secondary TN and should be considered
useful for distinguishing secondary TN from classical TN,
the absence of these clinical features does not rule out TN
secondary to MS [7, 18].
Pathophysiological mechanisms
Established knowledge postulates that TN secondary to
MS is associated with a pontine demyelinating plaque. A
neurophysiological and neuroimaging study in patients
with TN secondary to MS showed that the lesion involves
the anatomical area corresponding to the intrapontine
segment of the trigeminal nerve, an area centred in the
ventrolateral pons between the trigeminal root entry zone
(REZ) and the trigeminal nuclei, i.e. along the intrapontine
trigeminal primary afferents [15]. The role of the pontine
demyelinating plaque is also supported by functional neu-
roimaging studies showing that tensor imaging abnormal-
ities in patients with classical and idiopathic TN are
located in the cisternal and REZ segments of the trigemi-
nal nerve, whereas in patients with TN secondary to MS
the abnormalities are located in the pontine tract of the
trigeminal nerve [19]. Although TN secondary to MS has
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long been attributed exclusively to a demyelinating plaque
affecting the trigeminal REZ in the pons [15, 20, 21], the
plaque theory contrasts with the frequent neuroimaging
findings of neurovascular compression of the trigeminal
root in patients with TN secondary to MS and with the
observation in some MS patients that TN is the sole clin-
ical manifestation (Fig. 1) [22]. A prospective clinical and
neuroimaging study in patients with MS revealed a signifi-
cant association between neurovascular compression and
TN secondary to MS, thus suggesting that a pontine
plaque affecting the intra-axial primary afferents and
neurovascular compression in concert might cause TN
secondary to MS through a double-crush mechanism,
involving inflammatory demyelination and mechanical
demyelination, of the same first-order neurons [16].
There is broad consensus that the primary mechanism of
paroxysmal pain in TN is the focal demyelination of pri-
mary afferents at the entry of the trigeminal root into the
pons. This area represents a locus of minoris resistentiae
since it is here that Schwann cells are replaced by oligo-
dendroglia to form the myelin sheath [23]. As a result of
demyelination, the axons tend toward a depolarization
level, which makes them hyperexcitable. This, in turn,
produces ectopic excitation, high-frequency discharges and
ephaptic transmission from neighbouring, healthy nerve
fibres [24–26]. A possible secondary effect of the
hyperactivity of primary afferents is central sensitization of
wide-dynamic-range neurons in the trigeminal spinal
nucleus or changes that are even more central, but
more research is needed into these pathophysiological
mechanisms [27].
Focal demyelination is not the only mechanism under-
lying the development of paroxysmal pain in patients with
TN. The immediate pain relief following microvascular
decompression cannot be explained by a remyelination
process, thus suggesting a possible role of a transient con-
duction block. This hypothesis was supported by the imme-
diate recovery of trigeminal root conduction, demonstrated
by both scalp evoked potentials and direct root recordings,
after microvascular decompression [28].
Diagnostic tests
According to the classification and diagnostic grading sys-
tem for practice and research issued by the Special Interest
Group on Neuropathic Pain of the International Associ-
ation for the Study of Pain [3], the diagnosis of secondary
TN relies on the demonstration of a major neurologic
disease that damages the trigeminal pathway and causes
neuralgia. In patients with TN secondary to MS, neuro-
physiological techniques and MRI are commonly used to
provide a definite evidence of trigeminal pathway impair-
ment [18]. Although various neurophysiological techniques
can be used to assess the trigeminal system, trigeminal
reflex testing has a diagnostic specificity and sensitivity
Fig. 1 Neuroimaging findings in a representative patient with TN
secondary to MS possibly due to a double crush mechanism. 3D time-
of-flight (TOF) magnetic resonance angiography scans (a) and 3D
constructive interference in the steady state (CISS) T2-weighted (b) on
the axial plane demonstrate left neurovascular compression (NVC) with
associated trigeminal nerve atrophy. T2-weighted image on the axial
plane shows a hyperintense pontine lesion at the left trigeminal nerve
root entry zone (REZ) (c). The arrow indicates the trigeminal nerve (b)
and the arrowhead the demyelinating plaque (c). Reproduced from [16]
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close to 90% for identifying trigeminal pathway impairment
in patients with secondary TN [5]. This technique is easier
and less invasive than the evoked-potential technique, with
the finding of any abnormality suggesting an underlying
structural lesion. The trigeminal reflexes consist of a series
of reflex responses (R1 and R2 components of the blink re-
flex after electrical stimulation of the ophthalmic division,
SP1 and SP2 components of the masseter inhibitory reflex
after electrical stimulation of the maxillary or mandibular
division) that assess the functioning of the trigeminal affer-
ents from all trigeminal territories, as well as the trigeminal
central circuits in the midbrain, pons and medulla [29]. Tri-
geminal reflex testing is abnormal in 89% of patients with
TN secondary to MS but in only 3% of patients with clas-
sical and idiopathic TN [5]. In patients without a relevant
pontine plaque and with normal trigeminal reflex testing,
one can speculate whether it is theoretically plausible that
classical or idiopathic TN can co-exist with MS in one and
the same patient.
MRI is routinely used for diagnosing MS and identifying
TN secondary to MS. In patients with TN secondary to
MS, T2-weighted MRI scans identify any linear plaques in
the ventrolateral pons located between the trigeminal root
entry zone and the trigeminal nuclei and involving the
intrapontine part of primary afferents of the trigeminal
nerve [15, 30]. Conversely, brainstem lesions in patients
with MS-related trigeminal sensory disturbances other
than TN (ongoing pain, dysesthesia or hypoesthesia) are
more scattered, with lesions most likely to be found in the
region involving the subnucleus oralis of the spinal
trigeminal complex (Fig. 2) [15].
Since MRI can be used to reliably investigate the
anatomy and vascular relationships of the trigeminal nerve,
it is useful for assessing the neurovascular compression of
the trigeminal nerve at the root entry zone. Previous
studies showed that neurovascular compression, i.e. with
morphological changes of the trigeminal nerve such as
atrophy, dislocation, indentation or flattening, was highly
associated with the symptomatic side in TN patients with
MS [16, 31]. This finding indicates a more complex disease
aetiology with at least two causes of demyelination in some
TN patients with MS.
Admittedly, the MRI identification of a pontine plaque
in patients with confirmed MS do not probably influence
treatment strategies. Conversely, the MRI investigation of
the neurovascular conflict may be important for planning
microvascular decompression as surgical treatment.
Treatment
Pharmacological treatment
Pharmacological treatment of TN secondary to MS is
challenging owing to the poor tolerability of drugs and the
lack of evidence-based information in the literature. There
are no placebo-controlled studies, and the studies that do
exist are small, open-label trials based on carbamazepine
(CBZ), lamotrigine, gabapentin, topiramate, misoprostol or
combination therapies [32–43]. These case series reported
potential efficacy of lamotrigine as monotherapy or associ-
ated with gabapentin or carbamazepine, topiramate and
gabapentin. Pregabalin was tested in a pilot study investi-
gating the effect on painful paroxysmal symptoms in six-
teen patients with MS, including two patients with TN [35].
Lamotrigine, with a mean dosage of 170mg daily, signifi-
cantly reduced pain related to TN in a group of 18 patients
with MS [33]. In a recent, prospective, open-label, pilot
study five patients with TN secondary to MS were success-
fully treated by a combination treatment of pregabalin plus
lamotrigine [43]. The effect of topiramate was tested in six
patients with MS and TN refractory to conventional med-
ical therapy. Five out of six patients treated with topiramate
(50–300mg/day) reported complete pain relief [36]. Three
studies reported efficacy of misoprostol (a prostaglandin-
E1-analogue) in a total of 28 patients with TN secondary to
MS [37, 44, 45]. Reder and Arnason reported that miso-
prostol (300–800 μg) relieved pain in six of seven patients
who had failed to respond to conventional pharmacologic
therapy, without serious side effects [37]. DMKG study
group tested the effect of misoprostol (600 μg) in refractory
TN associated with MS. Eighteen patients completed the
study period and 14 of them showed a reduction of more
than 50% in attack frequency and intensity beginning five
days after treatment onset. There were only mild and tran-
sient drug-related side effects in three patients [45]. Ac-
cording to the international guidelines [18], there is
insufficient evidence to support or refute the effectiveness
of any medication in treating pain in TN secondary to MS.
It is, however, generally agreed that the first line therapy is
pharmacological and is based, as it is for classical and idio-
pathic TN, on the use of sodium-channel blockers, i.e. CBZ
and oxcarbazepine (OXC) [46, 47]. These drugs block
voltage-gated sodium-channels in a frequency-dependent
manner and consequently reduce their action-potential fir-
ing frequency. Placebo-controlled trials in patients with
classical and idiopathic TN demonstrated the efficacy of
CBZ [48, 49], with a number needed to treat to obtain im-
portant pain relief of 1.7–1.8 [50]. However, this efficacy in
classical and idiopathic TN is compromised by the toler-
ability, with a number needed to harm of 3.4 for minor ad-
verse events and of 24 for severe adverse events [51, 52].
The most frequent adverse effects involve the central ner-
vous system, and include somnolence, dizziness and pos-
tural imbalance. OXC has a comparable efficacy to that of
CBZ but a greater tolerability [53] (except of the risk of
hyponatremia) and a lower potential for drug interaction
[54, 55]. In TN secondary to MS, many patients never ad-
vance to the regimen required for pain relief because of in-
tolerable adverse effects. CBZ and OXC can result in
adverse effects that mimic a disease exacerbation, and the
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sudden onset or sudden worsening of common MS symp-
toms may, consequently, be erroneously treated with intra-
venous steroids [32, 56]. As in classical and idiopathic TN,
these drugs may be combined with lamotrigine, baclofen,
pregabalin or gabapentin in patients that are unable to
attain a full dosage of CBZ or OXC because of side
effects [57].
Patients suffering from persistent pain between the
paroxysms are more resistant to CBZ and OXC [57]. These
drugs produce a frequency-dependent block of voltage-
gated sodium channels and, thereby, by reducing the fre-
quency of action potential firing, they effectively reduce
paroxysmal pain; however, they have a far less positive ef-
fect on concomitant persistent pain. According to clinical
experience, gabapentinoids and antidepressants might be
more effective in persistent than in paroxysmal pain and
are often tried as an add-on to OXC or CBZ in patients
with the atypical form of TN with concomitant persistent
pain [57]. No trial, however, has directly assessed the effi-
cacy of this combination in patients with persistent pain
and there is no evidence to support or refute its use in
clinical practice [57].
A recent phase 2A study investigated the efficacy of a
novel selective sodium-channel 1.7 blocker in patients
with classical TN [58]. This novel drug, which targets
nociceptive sodium-channel afferents and has no effect on
the CNS, is likely to be tolerated better than CBZ and
OXC.
Fig. 2 Voxel-based analysis in patients with TN secondary to MS. Voxel-based brainstem model in patients with TN secondary to MS (TN group, n =
42) and in patients with trigeminal sensory disturbances due to MS (non-TN group, n = 29). The statistical analysis in patients with TN secondary to MS
showed an area of very high probability of a lesion (P < 0.0001) centred in the ventrolateral pons between the trigeminal root entry zone and the
trigeminal nuclei, i.e. along the intrapontine part of the trigeminal primary afferents. In the non-TN group, the area of high probability of lesion (P <
0.001) corresponded to a more caudal, medial, and dorsal pontine region involving the subnucleus oralis of the spinal trigeminal complex. The axial
sections in this figure correspond to the sections 120 and 160 of the Shaltenbrandt atlas. The level of probability is colour-coded. Blue indicates non-
significant areas, white the minimum level of significance (P < 0.05), and red the highest level of significance. Reproduced from [15]
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Surgical treatments
Although the role of surgery in the management of TN
secondary to MS remains uncertain [18], it is generally
agreed that patients who do not respond to or cannot at-
tain the therapeutic dosage required should be informed
of the availability of surgery [22, 59, 60]. Reported out-
comes on case series of TN patients with MS indicate
that surgical procedures in such patients tend to be less
effective than in patients with classical and idiopathic
TN [61–63]. The majority of available neurosurgical
studies, however, are retrospective and without inde-
pendent assessors of outcome.
A reduced long-term benefit in comparison with patients
with classical and idiopathic TN and the occurrence of po-
tentially serious adverse events suggest that surgical proce-
dures should be reserved for medically refractory patients.
Several authors have suggested that continuous pain in
patients with TN is associated with poorer outcome after
surgical intervention [47, 51] but this conclusion is still
controversial. Surgical procedures include peripheral lesions
distal to the ganglion, gasserian ganglion percutaneous
techniques, stereotactic radiosurgery and microvascular de-
compression in the posterior fossa [64–66]. The first group
of surgical methods includes peripheral lesions of the tri-
geminal terminal nerves at their emergence from the facial
bones: neurectomy, alcohol injections, radiofrequency
lesions, or cryolesions. These procedures are usually well
tolerated but none of these methods has ever been
supported by adequate trials [67].
Percutaneous ganglion lesions include thermocoagula-
tion by radiofrequency, chemical lesions by injection of
high-concentration glycerol and mechanical compression
by balloon inflation. Even though results vary in different
case series, no convincing superiority of any surgical
method has emerged in this patient category [68]. The
major risks of all percutaneous ganglion lesion procedures
are piercing of the maxillary artery and that of the dura
mater covering the Meckel cave, with various possible
consequences, from burning of an oculomotor nerve to
infusion of glycerol into the CSF of the middle cranial
fossa. Trigeminal sensory deficits are almost unavoidable;
these are usually transient with balloon compression and
glycerol injection and more severe and longer lasting after
radiofrequency [68, 69].
Several studies with a follow-up exceeding one year have
investigated the role of surgical procedures designed to le-
sion the Gasserian ganglion. Procedures were performed
chemically by glycerol injections [61, 70–72], mechanically
by balloon compression [73–76], or thermically by radio-
frequency thermocoagulation [64, 77–79]. Although most
patients enrolled in these studies reported complete acute
pain relief following the lesioning procedures, the recur-
rence rate during follow-up and the frequency of adverse
events varied widely (Table 1). In the case series by
Mohammad-Mohammadi and colleagues, a total of 96
patients underwent 277 procedures to treat TN secondary
to MS, including percutaneous glycerol injection, balloon
compressions, stereotactic radiosurgery, radiofrequency
thermocoagulation and microvascular decompression.
Symptoms recurred in 66% of patients and 181 proce-
dures were performed for symptom recurrence. As an ini-
tial procedure, balloon compression had the highest initial
pain-free response and median pain-free intervals,
followed by glycerol injection [59]. There are no signifi-
cant differences in the frequency of complications associ-
ated with the lesioning procedures. Each patient should
thus be thoroughly informed of the advantages and limita-
tions of each procedure, so that the most appropriate one
can be chosen with the surgeon as an alternative option
for the treatment of TN secondary to MS.
Other studies with a follow-up exceeding one year have
investigated the role of stereotactic radiosurgery in patients
with TN secondary to MS [65, 80–83]. The probability of
remaining pain-free without resorting to medication in five
years and the frequency of adverse events are still unclear.
In one case series of TN patients with MS who underwent
stereotactic radiosurgery, only 38% of the patients were still
pain-free without drugs after five years. The frequency of
complications, which consist of trigeminal sensory distur-
bances was ranging widely from 5 to 57% [84]. A recent
retrospective review of long-term outcomes involving 42
patients showed that the proportion of patients with pain
relief after stereotactic radiosurgery was 62%, 29%, 22%,
and 13% at 1, 3, 5, and 7 years [85]. Unlike the other types
of intervention, the pain-relieving effect of stereotactic ra-
diosurgery is not immediate and generally requires 6 to 8
weeks to develop. Another issue is the reliability and accur-
acy of the methods of finding the exact coordinates of the
trigeminal root just before its entrance into the pons,
where the radiation beams should collimate. On the other
hand, stereotactic radiosurgery is associated with a lower
rate of adverse events than Gasserian ganglion procedures.
These two techniques may be therefore considered as valu-
able alternatives for treating TN secondary to MS, with the
choice between them being based on the patient’s and sur-
geon’s preferences. Retrospective studies have compared
the efficacy of stereotactic radiosurgery and Gasserian gan-
glion procedures [70, 86]. These studies have shown that
patients treated with Gasserian ganglion procedures ex-
perience immediate pain relief and do not need to resort to
TN drugs for longer periods than patients treated with
stereotactic radiosurgery. In a recent study involving a
small sample of patients radiofrequency thermocoagulation
and stereotactic radiosurgery provide initial pain relief in
71% of patients. Over time, 60% of radiofrequency thermo-
coagulation and 29% of stereotactic radiosurgery patients
required additional procedures to obtain satisfactory pain
relief [87].
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The conventional opinion that MS is an absolute
contraindication to microvascular decompression, due to
the supposed exclusive causative role of a demyelinating
lesion affecting the trigeminal root entry zone, has been
contrasted by some studies supporting the role of vascular
compression in MS patients [22, 88, 89]. Neurovascular
compression may act as a concurring mechanism that
leads to the focal demyelination of primary afferents near
the entry of the trigeminal root into the pons. This hy-
pothesis is supported by the fact that severe neurovascular
compression at the trigeminal root entry zone is found in
most patients during surgery (from 50% to 100% of pa-
tients with TN secondary to MS) [20, 90, 91]. Microvascu-
lar decompression in patients with classical TN produces
Table 1 Summary of studies dealing with gangliolysis techniques and gamma knife radiosurgery in patients with multiple sclerosis-
related trigeminal neuralgia
Gasserian ganglion percutaneous techniques
Author Procedure no Complete pain
relief* (%)
Mean follow-up
(months)
Complication
rate (%)
Recurrence
rate (%)
Broggi, 1982 Radiofrequency rhizotomy 14 100 NA NA 40
Hooge and Redekop, 1995 Radiofrequency rhizotomy 17 57 72 NA 43
Kanpolat, 2000 Radiofrequency rhizotomy 17 70,6 60 76,5 29,4
Berk, 2003 Radiofrequency rhizotomy 13 81 52 0 50
Mallory, 2012 Radiofrequency rhizotomy 67 40 28.3 3 54
Holland, 2017 Radiofrequency rhizotomy 10 71 66 66 60
Dieckmann, 1987** Glycerol rhizotomy 21 NA NA NA 40
Kondziolka, 1994 Glycerol rhizotomy 53 60 36 0 40
Pickett, 2005 Glycerol rhizotomy 53 78 81 20 59
Mathieu, 2012 Glycerol rhizotomy 18 100 38 66,7 38.9
Mohammad-Mohammadi, 2013 Glycerol rhizotomy 39 74 68,4 3 69
Kouzounias, 2010 Balloon compression 17 88 20 0 70,5
Mallory, 2012 Balloon compression 69 26 17.8 17.4 64
Montano, 2012 Balloon compression 21 81 51,5 0 57
Mohammad-Mohammadi, 2013 Balloon compression 19 95 68,4 5 61
Bergenheim, 2013** Balloon compression 23 NA NA NA NA
Martin, 2015 Balloon compression 17 82 43 21 86
Alvarez-Pinzon, 2016 Balloon compression 78 87 18 21 NA
Rogers, 2002 Stereotactic radiosurgery 15 80 17 13 33.3
Zorro, 2009 Stereotactic radiosurgery 37 62.1 56.7 5.4 37.8
Verheul, 2010 Stereotactic radiosurgery 13 90 16 37 35
Mathieu, 2012 Stereotactic radiosurgery 27 89 39 22.2 51.9
Weller, 2014 Stereotactic radiosurgery 35 35 39 39 40.7
Tuleasca, 2014 Stereotactic radiosurgery 43 90.7 53.8 16 61.5
Alvarez-Pinzon, 2016 Stereotactic radiosurgery 124 23 24 10 NA
Holland, 2017 Stereotactic radiosurgery 7 71 10 60 29
Conti, 2017 Stereotactic radiosurgery 27 85 37 26 56
Colin, 2018 Stereotactic radiosurgery 42 62 78 10 87
Broggi et al., 2004 Microvascular decompression 35 39 44 NA NA
Athanasiou et al., 2005 Microvascular decompression 5 100 38.8 0 20
Eldridge et al., 2003 Microvascular decompression 9 100 12 11 66
Sandell T and Eide, 2010 Microvascular decompression 15 47 65 33 NA
Ariai et al., 2014 Microvascular decompression 10 80 14 10 60
NA not available
*Pain relief with no need of pharmacological treatment
**These studies investigated patients with classical and MS-related TN and does not provide distinct data of the two conditions
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immediate pain relief in the majority of patients. However,
when applied to patients with TN secondary to MS, this
technique is generally reported to be less effective than in
patients with classical TN. Indeed, after five years fewer
than 50% of the patients in the case series described by
Broggi and 15% in the case series described by Ariai were
still pain-free (in comparison with approximately 80% of
pain-free patients after surgery for classical TN). The ad-
verse event rate of microvascular decompression is very
low. In the two aforementioned case series, only one pa-
tient suffered long-term morbidity (facial nerve palsy). In
larger case series by Barker et al. on microvascular decom-
pression in patients with classical TN, the rate of adverse
events was also low but included death (0.2%), brainstem
infarction (0.1%), cerebellar hematoma and edema (0.5%)
and severe or permanent cranial nerve damage (3%). This
major surgical procedure requires general anesthesia, in-
tubation and craniotomy. Given the serious nature of
some of the reported adverse events, thorough presurgical
patient information is important [92].
The reduced efficacy of microvascular decompression in
TN secondary to MS points to the crucial role of the pon-
tine demyelinating plaque in most patients with this form
of TN; however, the observation that this surgical proced-
ure is still effective in many patients lends support to the
involvement of neurovascular compression in TN second-
ary to MS. On the other hand, we cannot exclude that,
during microvascular decompression, manipulation of the
trigeminal root may be a sufficiently traumatic procedure
to disrupt the parossistic discharge behaviour of the axons.
Before drawing definitive conclusions, we must await
further high-quality evidence demonstrating that micro-
vascular decompression is indeed an effective technique.
Further studies using advanced neuroimaging techniques
like diffusion tensor imaging (DTI) and 3.0 Tesla MRI are
also warranted. Possibly, such studies have the potential to
identify the trigeminal anatomical abnormalities that can
predict the outcome of the different neurosurgical proce-
dures and thereby guide future clinical decision-making
and patient information.
Conclusions and future perspectives
Patients with MS suffer from various types of neuropathic
pain, the most severe being TN, which has a significant im-
pact on quality of life [1]. The relatively poor tolerability of
the sedative and motor side effects of the centrally-acting
drugs CBZ and OXC highlight the need to develop new
selective and better-tolerated sodium-channel blockers. A
new selective sodium-channel 1.7 blocker is under develop-
ment [58].
Although there is evidence demonstrating that neuro-
vascular compression may act as a concurring mechanism
in some patients with TN secondary to MS, we still lack
high-quality research assessing the efficacy of microvascular
decompression in MS patients. Hence, prospective studies
using independent assessors of outcome and advanced
neuroimaging techniques should focus on how trigeminal
anatomical abnormalities may be able to predict the effi-
cacy of microvascular decompression.
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